Cogent Biosciences, Inc.
COGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $125 | $128 | $126 | $98 |
| Short-Term Investments | $266 | $110 | $120 | $189 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $7 | $7 | $9 |
| Total Curr. Assets | $397 | $245 | $253 | $296 |
| Property Plant & Equip (Net) | $24 | $25 | $26 | $27 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $5 | $5 | $5 |
| Total NC Assets | $29 | $30 | $31 | $31 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $426 | $275 | $284 | $328 |
| Liabilities | – | – | – | – |
| Payables | $16 | $17 | $14 | $12 |
| Short-Term Debt | $2 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $45 | $40 | $34 | $42 |
| Total Curr. Liab. | $62 | $58 | $49 | $56 |
| LT Debt | $59 | $59 | $15 | $16 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $0 | $0 |
| Total NC Liab. | $61 | $61 | $15 | $16 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $16 | $17 | $17 | $17 |
| Total Liabilities | $123 | $120 | $65 | $72 |
| Equity | – | – | – | – |
| Pref Stock | $108 | $108 | $108 | $111 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,086 | -$1,005 | -$931 | -$859 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,280 | $1,052 | $1,042 | $1,005 |
| Total Equity | $302 | $155 | $219 | $256 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $426 | $275 | $284 | $328 |
| Net Debt | -$65 | -$67 | -$109 | -$81 |